CAPTRUST Financial Advisors
CALT

CAPTRUST Financial Advisors’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-85
Closed -$2K – 4255
2022
Q2 		$2K Hold
85
– – ﹤0.01% 4539
2022
Q1 		$2K Buy
+85
New +$1.7K ﹤0.01% 4566

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CAPTRUST Financial Advisors's CALT Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2022, closing a stake of 85 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in CALT in Q1 2022 and held it in 2 quarters. The position peaked at $2K in Q2 2022. 16 funds tracked by Wall St. Rank hold CALT as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 85 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q1 2022 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Calliditas Therapeutics AB American Depositary Shares position peaked at $2K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.